Indeed. I have an opportunity to participate an autologus mesenchymal stem cell trial for crohn's, so I have made some research about the treatment, procedure and its effectiveness on crohn's disease. It seems very efficient for crohn's fistulas(they inject the cells directly to the fistulas) but not very efficient for crohn's disease in general (inflammation). For crohn's disease they give the cells intravenously. The procedure has not matured for crohn's disease yet but it seems very safe.
I have downloaded some materials on Autologus MSC for crohn's. Here some copy paste:
Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
Duijvestein M1, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW.
Author information
Abstract
BACKGROUND AND AIM:
Mesenchymal stromal cells (MSCs) are pluripotent cells that have immunosuppressive effects both in vitro and in experimental colitis. Promising results of MSC therapy have been obtained in patients with severe graft versus host disease of the gut. Our objective was to determine the safety and feasibility of autologous bone marrow derived MSC therapy in patients with refractory Crohn's disease.
PATIENTS AND INTERVENTION:
10 adult patients with refractory Crohn's disease (eight females and two males) underwent bone marrow aspiration under local anaesthesia. Bone marrow MSCs were isolated and expanded ex vivo. MSCs were tested for phenotype and functionality in vitro. 9 patients received two doses of 1-2×10(6) cells/kg body weight, intravenously, 7 days apart. During follow-up, possible side effects and changes in patients' Crohn's disease activity index (CDAI) scores were monitored. Colonoscopies were performed at weeks 0 and 6, and mucosal inflammation was assessed by using the Crohn's disease endoscopic index of severity.
RESULTS:
MSCs isolated from patients with Crohn's disease showed similar morphology, phenotype and growth potential compared to MSCs from healthy donors. Importantly, immunomodulatory capacity was intact, as Crohn's disease MSCs significantly reduced peripheral blood mononuclear cell proliferation in vitro. MSC infusion was without side effects, besides a mild allergic reaction probably due to the cryopreservant DMSO in one patient. Baseline median CDAI was 326 (224-378). Three patients showed clinical response (CDAI decrease ≥70 from baseline) 6 weeks post-treatment; conversely three patients required surgery due to disease worsening.
CONCLUSIONS:
Administration of autologous bone marrow derived MSCs appears safe and feasible in the treatment of refractory Crohn's disease. No serious adverse events were detected during bone marrow harvesting and administration.
[Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases].
[Article in Russian]
Lazebnik LB, Konopliannikov AG, Kniazev OV, Parfenov AI, Tsaregorodtseva TM, Ruchkina IN, Khomeriki SG, Rogozina VA, Konopliannikova OA.
Abstract
AIM:
to determine the whether mesenchymal stem cells (MSC) may be used in the treatment of patients with chrOnic intestinal inflammatory diseases (IID).
SUBJECTS AND METHODS:
Thirty-nine patients with ulcerative colitis (UC) (Group 1) and 11 with Crohn's disease (CD) (Group 2) were examined. Comparative groups included 30 patients with UC (Group 2) and 10 with CD (Group 4). Two-three days before MSC administration, immunodepressants were discontinued, the dosage of corticosteroids was reduced to 15-20 mg/day, and that of aminosalicylates remained to be 2 g/day. The results were quantified using the mean values of the Rachmilewich clinical activity index, the Crohn's disease activity index and the Mayo and Gebs scales. The patients were followed up for 4-8 months. Humoral immunological indices (cytokines, autologous antibodies) were determined. Bone marrow cells were obtained from the donor sternum or iliac crest. Cultivation at the end of weeks 5-6 provided a population of allogeneic donor MSC in a quantity of (1.5-2) x 10(8) tells required for transplantation to a patient. MSC cultures were once injected intravenously in a dropwise fashion.
RESULTS:
A statistically significant decrease in the indices of the clinical and morphological activities of an inflammatory process was noted in 39 patients with UC and in 11 patients with CD as compared with the comporison groups after MSC transplantation. Clinicomorphological remission occurred in 40 patients. Inclusion of MSC into the treatment program was ineffective in 8 patients with UC and in 2 patients with CD. The use of MSC made it possible to discontinue corticosteroids in 34 of the 50 patients with the hormone-dependent and hormone-resistant forms of UC and CD and to reduce the dose of prednisolone to 5 mg/day in 7 patients, by administering 5-aminosalicylic acid only.
CONCLUSION:
The use of MSC may be appreciated as a new strategic direction of therapy for IID. The intravenously administered stem cells exert a potent immunomodulatory effect, reduce the activity of autoimmune inflammation, and stimulate a reparative process in the intestinal mucosa.
Negative impact of bone-marrow-derived mesenchymal stem cells on dextran sulfate sodium-induced colitis.
Nam YS1, Kim N1, Im KI1, Lim JY1, Lee ES1, Cho SG1.
Author information
Abstract
AIM:
To investigate the effects of mesenchymal stem cells (MSCs) on dextran sulfate sodium-induced inflammatory bowel disease (IBD).
METHODS:
C57BL/6 mice were fed 3.5% (g/L) dextran sulfate sodium. On day seven, the mice received intraperitoneal injections of 1 × 10(6) MSCs. The survival rate, disease activity index values, and body weight, were monitored daily. On day ten, colon lengths and histopathologic changes were assessed. In addition, immunoregulatory changes following MSC administration were evaluated by determining the levels of effector T cell responses in the spleen and mesenteric lymph nodes, and the expression levels of inflammatory cytokines in homogenized colons.
RESULTS:
Intraperitoneal administration of MSCs did not prevent development of colitis and did not reduce the clinicopathologic severity of IBD. No significant difference was evident in either survival rate or disease activity index score between the control and MSC-treated group. Day ten-sacrificed mice exhibited no significant difference in either colon length or histopathologic findings. Indeed, the MSC-treated group exhibited elevated levels of interleukin (IL)-6 and transforming growth factor-β, and a reduced level of IL-10, in spleens, mesenteric lymph nodes, and homogenized colons. The IL-17 level was lower in the mesenteric lymph nodes of the MSC-treated group (P = 0.0126). In homogenized colons, the IL-17 and tumor necrosis factor-α (P = 0.0092) expression levels were also lower in the treated group.
CONCLUSION:
MSC infusion provided no significant histopathologic or clinical improvement, thus representing a limited therapeutic approach for IBD. Functional enhancement of MSCs is needed in further study.
A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation.
García-Olmo D1, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA.
Author information
Abstract
PURPOSE:
The effective management of fistulas in patients with Crohn's disease presents an extremely challenging problem. Mesenchymal adult stem cells extracted from certain tissues, such as adipose tissue, can differentiate into various cell types. Therefore, we have tried to use such cells to stimulate healing of Crohn's fistulas.
METHODS:
We designed a prospective Phase I clinical trial, involving five patients with Crohn's disease, to test the feasibility and safety of autologous stem cells transplantation in the treatment of fistulas. We also studied the expression of various cell markers and the growth rates of the lipoaspirate-derived cells that were used for transplantation.
RESULTS:
One patient was excluded because of bacterial contamination of cultured cells. We inoculated nine fistulas in four patients with autologous adipose tissue-derived stem cells at Passage 3 or earlier. Eight inoculated fistulas were followed weekly for at least eight weeks. In six fistulas, the external opening was covered with epithelium at the end of Week 8, and, thus, these fistulas were considered healed (75 percent). In the other two fistulas, there was only incomplete closure of the external opening, with a decrease in output flow (not healed; 25 percent). No adverse effects were observed in any patient at the end of the follow-up period (minimum follow-up,12 months; maximum follow-up, 30 months; follow-up average, 22 months).
CONCLUSIONS:
To our knowledge, this is the first report of a clinical trial of cell therapy using autologous stem cells obtained from a lipoaspirate. Our results indicate that our protocol is feasible and safe for the treatment of fistulas in Crohn's disease. The number of patients included and the uncontrolled nature of Phase I clinical trials do not allow demonstration of the effectiveness of the treatment. However, the results of the present study encourage to perform further studies in Phase II.
----------------------------------------------
For free full text articles, search these on google:
>>>
Mesenchymal stem cells: a new trend for cell therapy
Xin WEI1, Xue YANG2, Zhi-peng HAN3, Fang-fang QU3, Li SHAO1 , *, Yu-fang SHI2, *
Acta Pharmacologica Sinica (2013) 34: 747–754
© 2013 CPS and SIMM All rights reserved 1671-4083/13 $32.00
www.nature.com/aps
>>>
Successful Outpatient Treatment of Refractory Crohn’s Disease Using Adult Mesenchymal Stem Cells --------
(prochymal trial results, you can find this on their website.)
Data was presented at the October 2006 American College of Gastroenterology conference
Jane Onken, MD; Dianne Gallup, MS; John Hanson, MD; Michael Pandak, MD; Linda Custer, PhD*, Duke Clinical Research Institute, Durham NC and *Osiris Therapeutics, Baltimore MD
>>>Biol Res 45: 269-277, 2012
* Corresponding author: Fernando E. Figueroa, MD. Laboratorio de Inmunología Celular y Molecular, Facultad de Medicina Universidad de los Andes, Av. San Carlos de Apoquindo 2200,
Las Condes. Santiago, Chile. Postal Code: 7620001. Tel: (56)-2-4129455. E-mail address: ffi
[email protected] (F. Figueroa)
Received: Abril 5, 2012 . In Revised form: July 21, 2012. Accepted: September 3, 2012
Mesenchymal Stem Cell treatment for autoimmune diseases: a
critical review
Fernando E. Figueroa1,3,*, Flavio Carrión1, Sandra Villanueva2, Maroun Khoury3.
>>>
Role of mesenchymal stem cell therapy in Crohn’s disease
Jignesh Dalal1, Kimberly Gandy1 and Jos Domen1
